Skip Navigation


European Heart Journal Advance Access originally published online on May 4, 2005
European Heart Journal 2005 26(14):1347-1349; doi:10.1093/eurheartj/ehi308
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/14/1347    most recent
ehi308v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Verma, S.
Right arrow Articles by Strauss, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verma, S.
Right arrow Articles by Strauss, M. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE

Subodh Verma1,2,*, Lawrence A. Leiter3, Eva M. Lonn4 and Martin H. Strauss5

1Division of Cardiac Surgery, St Michael's Hospital and Toronto General Hospital, University of Toronto, Toronto, ON M5G 2CA, Canada
2Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
3Division of Endocrinology, St Michael's Hospital, Toronto, Ontario, Canada
4Division of Cardiology, McMaster University, Hamilton, Ontario, Canada
5Division of Cardiology, North York General Hospital, Toronto, Ontario, Canada

* Corresponding author. Tel: +1 416 340 4580; fax: +1 416 782 096. E-mail address: subodh.verma@sympatico.ca

This editorial refers to ‘The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy’{dagger} by C. Daly et al., on page 1369

The first 150 words of the full text of this article appear below.

PERSUADE,1 the diabetic substudy of the EUROPA trial, examined the role of the angiotensin-converting enzyme-inhibitor (ACE-I) perindopril 8 mg vs. placebo in patients with coronary artery disease and concomitant diabetes mellitus. The main results of EUROPA indicated a clinically and statistically significant reduction in the primary endpoint of death, non-fatal myocardial infarction (MI), and resuscitated cardiac arrest in patients with coronary artery disease treated with perindopril. Given the relatively small subgroup of patients in PERSUADE (n=1502), the results of this subgroup analysis did not reach statistical significance, although there was no heterogeneity observed between the PERSUADE and the EUROPA cohorts, indicating that the benefit of perindopril in diabetic patients was similar to that observed in the entire EUROPA cohort. Let us examine how the results of PERSUADE may impact on the use of ACE-I in people with diabetes.

The European Society of Cardiology, in a recent expert consensus document . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy
Caroline A. Daly, Kim M. Fox, Willem J. Remme, Michel E. Bertrand, Roberto Ferrari, Maarten L. Simoons, and on behalf of the EUROPA investigators
EHJ 2005 26: 1369-1378. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 CirculationHome page
M. H. Strauss and A. S. Hall
Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox
Circulation, August 22, 2006; 114(8): 838 - 854.
[Full Text] [PDF]

Home page
 StrokeHome page
M. H. Strauss, S. Verma, J. Schrader, S. Luders, A. Kulschewski, F. Hammersen, K. Plate, J. Berger, W. Zidek, P. Dominiak, et al.
MOSES Raises Questions * Response:
Stroke, February 1, 2006; 37(2): 338 - 340.
[Full Text] [PDF]